poisar

Stocks · News reference

BioCardia CEO Issued Shareholder Letter To Provide Update; Milestone Includes Submission For Japan's Pharmaceutical and Medical Device Agency Approval Planned For End Of 2026; Driving To Enroll Confirmatory CardiAMP HF II Trial In US

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BCDA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. SEC EDGAR

    8-K filing — BioCardia, Inc. (BCDA)

    Filed: 2026-08-24 AccNo: 0001437749-26-028778 Size: 178 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    BCDA
  3. Benzinga Newsdesk

    BioCardia Q2 EPS $(0.13) Beats $(0.18) Estimate

    BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 67.5 percent increase over losses of $(0.40) per share from the

    BCDA